Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2026Current Neuropharmacology

Statin Therapy for Primary Prevention in Adults Aged 80 Years and Older: A Systematic Review Conducted in Accordance with PRISMA 2020

View Full Paper
Ask AI
Bookmark
Share

Key result

Primary prevention statins in adults over 80 lack sufficient evidence for routine initiation.

Why the study?

Statins are well established for primary cardiovascular disease prevention up to approximately 75 years of age, but direct evidence in adults aged 80 years and older remains limited and extrapolation is uncertain.

Does statin therapy reduce cardiovascular events and mortality in adults aged 80 years and older without established atherosclerotic cardiovascular disease?

Population

12 studies or trial programs of older adults without established atherosclerotic cardiovascular disease

Comparison

Statin therapy vs control or non-use

Design

Systematic review conducted in accordance with PRISMA 2020

Authors

FEFrancisco EpeldeUniversitat Autònoma de Barcelona

Discussion

Loading...

Member takes

Implication

Insufficient evidence precludes routine statin initiation for primary prevention in adults ≥80; leaves open benefit-risk balance pending dedicated RCTs.

Key Points

  • To synthesize direct evidence on the efficacy and safety of statin therapy for the primary prevention of cardiovascular disease in adults aged 80 years and older.
  • Searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL through October 12, 2025, adhering to PRISMA 2020 guidelines with a prespecified protocol.
  • Included randomized trials, meta-analyses, and adjusted observational cohorts evaluating cardiovascular and functional outcomes in adults without established atherosclerotic cardiovascular disease.
  • Assessed methodological quality and risk of bias using RoB 2, the Newcastle-Ottawa Scale, or AMSTAR 2, and evaluated evidence certainty using GRADE.
  • Included 12 studies or trial programs, identifying minimal direct randomized clinical trial evidence specifically for primary prevention in adults aged 80 years and older.
  • Available trial subgroups showed mixed outcomes: ALLHAT-LLT found no benefit in adults aged ≥75 years, while JUPITER and HOPE-3 found cardiovascular reductions in adults aged ≥70 years but included few octogenarians.
  • Observational studies reported lower mortality and cardiovascular event rates among statin users, but these findings carried low to very low certainty due to healthy-user bias, residual confounding, and high heterogeneity that precluded formal meta-analysis.

Study Design

Type

Systematic Review

Structured PICO

Does statin therapy reduce cardiovascular events and mortality in adults aged 80 years and older without established atherosclerotic cardiovascular disease?

P
Population
Systematic review of 12 studies evaluating statin therapy for primary prevention of cardiovascular disease in adults aged 80 years and older.
I
Intervention
Statin therapy
C
Comparator
No statin therapy or placebo
O
Outcome
Major adverse cardiovascular events (MACE), myocardial infarction, stroke, all-cause and cardiovascular mortality, adverse events, cognition, disability, and functional outcomescomposite

Current evidence is insufficient to support routine statin initiation for primary prevention in adults aged 80 years and older, emphasizing the need for individualized shared decision-making.

Limitations

  • Healthy-user bias
  • Residual confounding
  • Heterogeneity in age strata and outcome definitions
  • No randomized trial provided a directly comparable, extractable estimate for this group
  • Minimal randomized evidence directly applicable to adults aged 80 years and older
  • Healthy-user bias in observational cohorts
  • Residual confounding in observational cohorts

Cite This Study

Francisco Epelde (2026) conducted a systematic review in Primary prevention of cardiovascular disease. Statin therapy was evaluated. Statin therapy for primary prevention in adults aged 80 years and older lacks sufficient direct evidence to support routine initiation, as randomized data are minimal and observational data are biased.

synapsesocial.com/papers/6a969a7f535111e2d4ce8caehttps://doi.org/10.2174/011570159x473652260816151554
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review2026
  2. 2Primary prevention statin therapy in older adults2022 · 21 citations
  3. 3Effectiveness of statins for primary prevention in the elderly - a propensity score matched cohort study2025
  4. 4Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study2026
  5. 5Initiating statins in the elderly: the evolving challenge2008 · 15 citations